The Rise and Fall of Hyaluronan in Respiratory Diseases

International Journal of Cell Biology

Volumn 2015, Issue , 2015, Pages

  Lauer, Mark E ^a   Dweik, Raed A ^a   Garantziotis, Stavros ^b   Aronica, Mark A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BLEOMYCIN; ELASTASE; HYALURONIC ACID; OZONE;

AGRICULTURAL WORKER; ARTIFICIAL VENTILATION; ASTHMA; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DUST; ENVIRONMENTAL EXPOSURE; FIRE FIGHTER; HUMAN; HYPEROXIA; LUNG INJURY; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; LUNG VENTILATION; NONHUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL LUNG DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RADIATION EXPOSURE; RESPIRATORY TRACT DISEASE; REVIEW; SMOKING;

EID: 84942278963     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2015/712507     Document Type: Review

References (150)

1. A. C. Petrey and C. A. de la Motte, "Hyaluronan, a crucial regulator of inflammation," Frontiers in Immunology, vol. 5, article 101, 2014.
2. A. Wang, C. de laMotte, M. Lauer, and V. Hascall, "Hyaluronan matrices in pathobiological processes," FEBS Journal, vol. 278, no. 9, pp. 1412-1418, 2011.
3. H. Frey, N. Schroeder, T. Manon-Jensen, R. V. Iozzo, and L. Schaefer, "Biological interplay between proteoglycans and their innate immune receptors in inflammation," The FEBS Journal, vol. 280, no. 10, pp. 2165-2179, 2013.
4. T. N. Wight, I. Kang, and M. J. Merrilees, "Versican and the control of inflammation," Matrix Biology, vol. 35, pp. 152-161, 2014.
5. D. Vigetti, E. Karousou, M. Viola, S. Deleonibus, G. de Luca, and A. Passi, "Hyaluronan: biosynthesis and signaling," Biochimica et Biophysica Acta-General Subjects, vol. 1840, pp. 2452-2459, 2014.
6. R. Stern, G. Kogan, M. J. Jedrzejas, and L. Šoltés, "The many ways to cleave hyaluronan," Biotechnology Advances, vol. 25, no. 6, pp. 537-557, 2007.
7. D. Jiang, J. Liang, and P. W. Noble, "Hyaluronan as an immune regulator in human diseases," Physiological Reviews, vol. 91, no. 1, pp. 221-264, 2011.
8. D. Jiang, J. Liang, and P. W. Noble, "Hyaluronan in tissue injury and repair," Annual Review of Cell and Developmental Biology, vol. 23, pp. 435-461, 2007.
9. R. Stern, A. A. Asari, and K. N. Sugahara, "Hyaluronan fragments: an information-rich system," European Journal of Cell Biology, vol. 85, no. 8, pp. 699-715, 2006.
10. H.-G. Wisniewski and J. Vilček, "TSG-6: an IL-1/TNF-inducible protein with anti-inflammatory activity," Cytokine and Growth Factor Reviews, vol. 8, no. 2, pp. 143-156, 1997.
11. E. Fries and A. Kaczmarczyk, "Inter-α-inhibitor, hyaluronan and inflammation," Acta Biochimica Polonica, vol. 50, no. 3, pp. 735-742, 2003.
12. C. M. Milner and A. J. Day, "TSG-6: a multifunctional protein associated with inflammation," Journal of Cell Science, vol. 116, no. 10, pp. 1863-1873, 2003.
13. C. M. Milner, V. A. Higman, and A. J. Day, "TSG-6: a pluripotent inflammatory mediator?" Biochemical Society Transactions, vol. 34, no. 3, pp. 446-450, 2006.
14. C. M. Milner, W. Tongsoongnoen, M. S. Rugg, and A. J. Day, "The molecular basis of inter-alpha-inhibitor heavy chain transfer on to hyaluronan," Biochemical Society Transactions, vol. 35, no. 4, pp. 672-676, 2007.
15. S. Swaidani, G. Cheng, M. E. Lauer et al., "TSG-6 protein is crucial for the development of pulmonary hyaluronan deposition, eosinophilia, and airway hyperresponsiveness in amurine model of asthma," The Journal of Biological Chemistry, vol. 288, no. 1, pp. 412-422, 2013.
16. M. E. Lauer, M. Aytekin, S. A. Comhair et al., "Modification of hyaluronan by heavy chains of inter-α-inhibitor in idiopathic pulmonary arterial hypertension," Journal of Biological Chemistry, vol. 289, no. 10, pp. 6791-6798, 2014.
17. S. Garantziotis, E. Zudaire, C. S. Trempus et al., "Serum inter-α-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury," American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 9, pp. 939-947, 2008.
18. F. E. Lennon and P. A. Singleton, "Role of hyaluronan and hyaluronan-binding proteins in lung pathobiology," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 301, no. 2, pp. L137-L147, 2011.
19. J. O. Cantor, "Potential therapeutic applications of hyaluronan in the lung," International Journal of Chronic Obstructive Pulmonary Disease, vol. 2, pp. 283-288, 2007.
20. S. Haserodt, A. Metin, and R. A. Dweik, "A comparison of the sensitivity, specificity, and molecular weight accuracy of three different commercially available hyaluronan ELISA-like assays," Glycobiology, vol. 21, no. 2, pp. 175-183, 2011.
21. L. Bjermer, A. Engström-Laurent, R. Lundgren, L. Rosenhall, and R. Hällgren, "Hyaluronate and type III procollagen peptide concentrations in bronchoalveolar lavage fluid as markers of disease activity in farmers lung," British Medical Journal, vol. 295, no. 6602, pp. 803-806, 1987.
22. Y. Cormier, M. Laviolette, A. Cantin, G. M. Tremblay, and R. Bégin, "Fibrogenic activities in bronchoalveolar lavage fluid of farmers lung," Chest, vol. 104, no. 4, pp. 1038-1042, 1993.
23. K. Larsson, A. Eklund, P. Malmberg, L. Bjermer, R. Lundgren, and L. Belin, "Hyaluronic acid (hyaluronan) in BAL fluid distinguishes farmers with allergic alveolitis from farmers with asymptomatic alveolitis," Chest, vol. 101, no. 1, pp. 109-114, 1992.
24. K. Larsson, A. Eklund, P. Malmberg, and L. Belin, "Alterations in bronchoalveolar lavage fluid but not in lung function and bronchial responsiveness in swine confinement workers," Chest, vol. 101, no. 3, pp. 767-774, 1992.
25. R. Brouwer, K. Biersteker, P. Bongers, B. Remijn, and D. Houthuijs, "Respiratory symptoms, lung function, and IgG4 levels against pig antigens in a sample of Dutch pig farmers," The American Journal of Industrial Medicine, vol. 10, no. 3, pp. 283-285, 1986.
26. M. Iversen, R. Dahl, J. Korsgaard, T. Hallas, and E. J. Jensen, "Respiratory symptoms in Danish farmers: an epidemiological study of risk factors," Thorax, vol. 43, no. 11, pp. 872-877, 1988.
27. K. Larsson, P. Malmberg, A. Eklund, L. Belin, and E. Blaschke, "Exposure to microorganisms, airway inflammatory changes and immune reactions in asymptomatic dairy farmers. Bronchoalveolar lavage evidence of macrophage activation and permeability changes in the airways," International Archives of Allergy and Applied Immunology, vol. 87, no. 2, pp. 127-133, 1988.
28. K. Wimander and L. Belin, "Recognition of allergic alveolitis in the trimming department of a Swedish sawmill," European Journal of RespiratoryDiseases. Supplement, vol. 107, pp. 163-167, 1980.
29. U. Johard, A. Eklund, M. Dahlqvist et al., "Signs of alveolar inflammation in non-smoking Swedishwood trimmers," British Journal of Industrial Medicine, vol. 49, no. 6, pp. 428-434, 1992.
30. U. Johard, A. Eklund, J. Hed et al., "Sawdust-induced inflammatory changes in rat lung: effects on alveolar and interstitial cells in relation to time," Inflammation, vol. 18, no. 5, pp. 547-563, 1994.
31. D. Sparrow, R. Bossé, B. Rosner, and S. T. Weiss, "The effect of occupational exposure on pulmonary function. A longitudinal evaluation of fire fighters and nonfire fighters," American Review of Respiratory Disease, vol. 125, no. 3, pp. 319-322, 1982.
32. P. W. Brandt-Rauf, B. Cosman, L. F. Fallon Jr., T. Tarantini, and C. Idema, "Health hazards of firefighters: acute pulmonary effects after toxic exposures," British Journal of Industrial Medicine, vol. 46, no. 3, pp. 209-211, 1989.
33. C. E. Bergström, A. Eklund, M. Sköld, and G. Tornling, "Bronchoalveolar lavage findings in firefighters," American Journal of Industrial Medicine, vol. 32, no. 4, pp. 332-336, 1997.
34. J. E. Alleman and B. T. Mossman, "Asbestos revisited," Scientific American, vol. 277, pp. 54-57, 1997.
35. E. Jamrozik, N. de Klerk, and A. W. Musk, "Asbestos-related disease," Internal Medicine Journal, vol. 41, no. 5, pp. 372-380, 2011.
36. A. M. Cantin, P. Larivée, M. Martel, and R. Bégin, "Hyaluronan (hyaluronic acid) in lung lavage of asbestos-exposed humans and sheep," Lung, vol. 170, no. 4, pp. 211-220, 1992.
37. E. Pluygers, P. Baldewyns, P. Minette, M. Beauduin, P. Gourdin, and P. Robinet, "Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations," European Journal of Cancer Prevention, vol. 1, no. 1, pp. 57-68, 1991.
38. J. Brisman, K. Torén, L. Lillienberg, G. Karlsson, and S. Ahlstedt, "Nasal symptoms and indices of nasal inflammation in flourdust-exposed bakers," International Archives of Occupational and Environmental Health, vol. 71, no. 8, pp. 525-532, 1998.
39. S. Garantziotis, Z. Li, E. N. Potts et al., "Hyaluronan mediates ozone-induced airway hyperresponsiveness in mice," The Journal of Biological Chemistry, vol. 284, no. 17, pp. 11309-11317, 2009.
40. S. Garantziotis, Z. Li, E. N. Potts et al., "TLR4 is necessary for hyaluronan-mediated airway hyperresponsiveness after ozone inhalation," American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 7, pp. 666-675, 2010.
41. M. L. Ormiston, G. R. D. Slaughter, Y. Deng, D. J. Stewart, and D. W. Courtman, "The enzymatic degradation of hyaluronan is associated with disease progression in experimental pulmonary hypertension," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 298, no. 2, pp. L148-L157, 2010.
42. K. R. Bracke, M. A. Dentener, E. Papakonstantinou et al., "Enhanced deposition of low-molecular-weight hyaluronan in lungs of cigarette smoke-exposed mice," American Journal of Respiratory Cell and Molecular Biology, vol. 42, no. 6, pp. 753-761, 2010.
43. J. Liang, D. Jiang, Y. Jung et al., "Role of hyaluronan and hyaluronan-binding proteins in human asthma," Journal of Allergy and Clinical Immunology, vol. 128, no. 2, pp. 403. e3-411. e3, 2011.
44. L. Eldridge, A. Moldobaeva, and E. M. Wagner, "Increased hyaluronan fragmentation during pulmonary ischemia," The American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 301, no. 5, pp. L782-L788, 2011.
45. M. T. Kuipers, T. van der Poll, M. J. Schultz, and C. W. Wieland , "Bench-to-bedside review: damage-associated molecular patterns in the onset of ventilator-induced lung injury," Critical Care, vol. 15, article 235, 2011.
46. C. A. McDevitt, G. J. Beck, M. J. Ciunga, and J. OBrien, "Cigarette smoke degrades hyaluronic acid," Lung, vol. 167, no. 1, pp. 237-245, 1989.
47. R. R. Kew, B. Ghebrehiwet, and A. Janoff, "Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement," The Journal of Clinical Investigation, vol. 75, no. 3, pp. 1000-1007, 1985.
48. C. M. Sköld, E. Blaschke, and A. Eklund, "Transient increases in albumin and hyaluronan in bronchoalveolar lavage fluid after quitting smoking: possible signs of reparative mechanisms," Respiratory Medicine, vol. 90, no. 9, pp. 523-529, 1996.
49. M. Decramer, W. Janssens, and M. Miravitlles, "Chronic obstructive pulmonary disease," The Lancet, vol. 379, no. 9823, pp. 1341-1351, 2012.
50. W. D. Song, A. C. Zhang, Y. Y. Pang et al., "Fibronectin and hyaluronan in bronchoalveolar lavage fluid fromyoung patients with chronic obstructive pulmonary diseases," Respiration, vol. 62, no. 3, pp. 125-129, 1995.
51. M. A. Dentener, J. H. J. Vernooy, S. Hendriks, and E. F. M. Wouters, "Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local inflammation," Thorax, vol. 60, no. 2, pp. 114-119, 2005.
52. J. A. Elias, C. G. Lee, T. Zheng, B. Ma, R. J. Homer, and Z. Zhu, "New insights into the pathogenesis of asthma," The Journal of Clinical Investigation, vol. 111, no. 3, pp. 291-297, 2003.
53. S. Sahu and W. S. Lynn, "Hyaluronic acid in the pulmonary secretions of patients with asthma," Biochemical Journal, vol. 173, no. 2, pp. 565-568, 1978.
54. A. M. Vignola, P. Chanez, A. M. Campbell et al., "Airway inflammation in mild intermittent and in persistent asthma," The American Journal of Respiratory and Critical CareMedicine, vol. 157, no. 2, pp. 403-409, 1998.
55. A. G. Ayars, L. C. Altman, S. Potter-Perigo, K. Radford, T. N. Wight, and P. Nair, "Sputum hyaluronan and versican in severe eosinophilic asthma," International Archives of Allergy and Immunology, vol. 161, no. 1, pp. 65-73, 2013.
56. D. Valeyre, A. Prasse, H. Nunes, Y. Uzunhan, P.-Y. Brillet, and J. Müller-Quernheim, "Sarcoidosis," The Lancet, vol. 383, no. 9923, pp. 1155-1167, 2014.
57. R. Hallgren, A. Eklund, A. Engstrom-Laurent, and B. Schmekel, "Hyaluronate in bronchoalveolar lavage fluid: a new marker in sarcoidosis reflecting pulmonary disease," British Medical Journal, vol. 290, no. 6484, pp. 1778-1781, 1985.
58. A. Eklund, R. Hällgren, E. Blaschke, A. Engström-Laurent, U. Persson, and B. Svane, "Hyaluronate in bronchoalveolar lavage fluid in sarcoidosis and its relationship to alveolar cell populations," European Journal of Respiratory Diseases, vol. 71, no. 1, pp. 30-36, 1987.
59. L. Bjermer, A. Engstrom-Laurent, M. Thunell, and R. Hallgren, "Hyaluronic acid in bronchoalveolar lavage fluid in patients with sarcoidosis: relationship to lavage mast cells," Thorax, vol. 42, no. 12, pp. 933-938, 1987.
60. E. Blaschke, A. Eklund, and R. Hernbrand , "Extracellularmatrix components in bronchoalveolar lavage fluid in sarcoidosis and their relationship to signs of alveolitis," American Review of Respiratory Disease, vol. 141, no. 4 I, pp. 1020-1025, 1990.
61. P. J. Wolters, H. R. Collard, and K. D. Jones, "Pathogenesis of idiopathic pulmonary fibrosis," Annual Review of Pathology, vol. 9, pp. 157-179, 2014.
62. L. Bjermer, R. Lundgren, and R. Hallgren, "Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis," Thorax, vol. 44, no. 2, pp. 126-131, 1989.
63. N. Milman, M. S. Kristensen, and K. Bentsen, "Hyaluronan and procollagen type III aminoterminal peptide in serum and bronchoalveolar lavage fluid from patients with pulmonary fibrosis," APMIS, vol. 103, no. 10, pp. 749-754, 1995.
64. Z. W. Ghamra and R. A. Dweik, "Primary pulmonary hypertension: an overview of epidemiology and pathogenesis," Cleveland Clinic Journal of Medicine, vol. 70, no. 1, pp. S2-S8, 2003.
65. E. Papakonstantinou, F. M. Kouri, G. Karakiulakis, I. Klagas, and O. Eickelberg, "Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension," European Respiratory Journal, vol. 32, no. 6, pp. 1504-1512, 2008.
66. M. Aytekin, S. A. A. Comhair, C. de laMotte et al., "High levels of hyaluronan in idiopathic pulmonary arterial hypertension," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 295, no. 5, pp. L789-L799, 2008.
67. P. N. Rao, A. Zeevi, J. Snyder et al., "Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation," Journal of Heart and Lung Transplantation, vol. 13, no. 6, pp. 958-962, 1994.
68. G. C. Riise, C. Kjellström, W. Ryd et al., "Inflammatory cells and activation markers in BAL during acute rejection and infection in lung transplant recipients: a prospective, longitudinal study," European Respiratory Journal, vol. 10, no. 8, pp. 1742-1746, 1997.
69. G. C. Riise, H. Scherstén, F. Nilsson, W. Ryd, and B. A. Andersson, "Activation of eosinophils and fibroblasts assessed by eosinophil cationic protein and hyaluronan in BAL: association with acute rejection in lung transplant recipients," Chest, vol. 110, no. 1, pp. 89-96, 1996.
70. M. Estenne, J. R. Maurer, A. Boehler et al., "Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria," Journal of Heart and Lung Transplantation, vol. 21, no. 3, pp. 297-310, 2002.
71. J. L. Todd, X. Wang, S. Sugimoto et al., "Hyaluronan Contributes to Bronchiolitis Obliterans Syndrome and Stimulates Lung Allograft Rejection through Activation of Innate Immunity," American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 5, pp. 556-566, 2014.
72. J. E. Adair, V. Stober, M. Sobhany et al., "Inter-α-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding," The Journal of Biological Chemistry, vol. 284, no. 25, pp. 16922-16930, 2009.
73. S. Garantziotis, J. W. Hollingsworth, R. B. Ghanayem et al., "Inter-alpha-trypsin inhibitor attenuates complement activation and complement-induced lung injury," The Journal of Immunology, vol. 179, no. 6, pp. 4187-4192, 2007.
74. G. Cheng, S. Swaidani, M. Sharma, M. E. Lauer, V. C. Hascall, and M. A. Aronica, "Hyaluronan deposition and correlation with inflammation in a murine ovalbumin model of asthma," Matrix Biology, vol. 30, no. 2, pp. 126-134, 2011.
75. G. Cheng, S. Swaidani, M. Sharma, M. E. Lauer, V. C. Hascall, and M. A. Aronica, "Correlation of hyaluronan deposition with infiltration of eosinophils and lymphocytes in a cockroachinduced murine model of asthma," Glycobiology, vol. 23, no. 1, pp. 43-58, 2013.
76. S. Ghosh, A. E. Samarasinghe, S. A. Hoselton, G. P. Dorsam, and J. M. Schuh, "Hyaluronan deposition and co-localization with inflammatory cells and collagen in a murine model of fungal allergic asthma," Inflammation Research, vol. 63, no. 6, pp. 475-484, 2014.
77. M. E. Lauer, G. Cheng, S. Swaidanis, M. A. Aronica, P. H. Weigel, and V. C. Hascall, "Tumor necrosis factor-stimulated gene-6 (TSG-6) amplifies hyaluronan synthesis by airway smooth muscle cells," Journal of Biological Chemistry, vol. 288, no. 1, pp. 423-431, 2013.
78. F. Chua, J. Gauldie, and G. J. Laurent, "Pulmonary fibrosis: searching for model answers," American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 1, pp. 9-13, 2005.
79. R. T. Dorr, "Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics," Seminars in Oncology, vol. 19, no. 2, pp. 3-8, 1992.
80. O. Nettelbladt, J. Bergh, M. Schenholm, A. Tengblad, and R. Hallgren, "Accumulation of hyaluronic acid in the alveolar interstitial tissue in bleomycin-induced alveolitis," American Review of Respiratory Disease, vol. 139, no. 3, pp. 759-762, 1989.
81. O. Nettelbladt, A. Tengblad, and R. Hallgren, "High-dose corticosteroids during bleomycin-induced alveolitis in the rat do not suppress the accumulation of hyaluronan (hyaluronic acid) in lung tissue," European Respiratory Journal, vol. 3, no. 4, pp. 421-428, 1990.
82. B. A. Bray, P. M. Sampson, M. Osman, A. Giandomenico, and G. M. Turino, "Early changes in lung tissue hyaluronan (hyaluronic acid) and hyaluronidase in bleomycin-induced alveolitis in hamsters," American Review of Respiratory Disease, vol. 143, no. 2, pp. 284-288, 1991.
83. O. Nettelbladt, A. Scheynius, J. Bergh, A. Tengblad, and R. Hällgren, "Alveolar accumulation of hyaluronan and alveolar cellular response in bleomycin-induced alveolitis," European Respiratory Journal, vol. 4, no. 4, pp. 407-414, 1991.
84. P. Teder, R. W. Vandivier, D. Jiang et al., "Resolution of lung inflammation by CD44," Science, vol. 296, no. 5565, pp. 155-158, 2002.
85. A. M. Dygai, E. G. Skurikhin, N. N. Ermakova et al., "Antifibrotic activity of hyaluronidase immobilized on polyethylenoxide under conditions of bleomycin-induced pneumofibrosis," Bulletin of Experimental Biology and Medicine, vol. 154, no. 3, pp. 388-392, 2013.
86. O. Nettelbladt, K. Lundberg, A. Tengblad, and R. Hällgren, "Accumulation of hyaluronan in bronchoalveolar lavage fluid is independent of iron-, complement-and granulocyte-depletion in bleomycin-induced alveolitis in the rat," European Respiratory Journal, vol. 3, no. 7, pp. 765-771, 1990.
87. J. Hernnas, O. Nettelbladt, L. Bjermer, B. Sarnstrand , A. Malmstrom, and R. Hallgren, "Alveolar accumulation of fibronectin and hyaluronan precedes bleomyin-induced pulmonary fibrosis in the rat," European Respiratory Journal, vol. 5, no. 4, pp. 404-410, 1992.
88. A. Zaman, Z. Cui, J. P. Foley et al., "Expression and role of the hyaluronan receptor RHAMMin inflammation after bleomycin injury," American Journal of Respiratory Cell and Molecular Biology, vol. 33, no. 5, pp. 447-454, 2005.
89. R. C. Savani, G. Hou, P. Liu et al., "A role for hyaluronan in macrophage accumulation and collagen deposition after bleomycin-induced lung injury," The American Journal of Respiratory Cell and Molecular Biology, vol. 23, no. 4, pp. 475-484, 2000.
90. H.-W. Zhao, L. Ü. Chang-Jun, and R.-J. Yu, "An increase in hyaluronan by lung fibroblasts: a biomarker for intensity and activity of interstitial pulmonary fibrosis?" Respirology, vol. 4, no. 2, pp. 131-138, 1999.
91. P. Teder, O. Nettelbladt, and P. Heldin, "Characterization of the mechanism involved in bleomycin-induced increased hyaluronan production in rat lung," American Journal of Respiratory Cell and Molecular Biology, vol. 12, no. 2, pp. 181-189, 1995.
92. I. N. Zelko and R. J. Folz, "Extracellular superoxide dismutase attenuates release of pulmonary hyaluronan from the extracellular matrix following bleomycin exposure," FEBS Letters, vol. 584, no. 13, pp. 2947-2952, 2010.
93. M. A. Antunes and P. R. M. Rocco, "Elastase-induced pulmonary emphysema: insights from experimental models," Anais da Academia Brasileira de Ciencias, vol. 83, no. 4, pp. 1385-1395, 2011.
94. M. Moczar, C. Lafuma, F. Lange, J. Bignon, L. Robert, and E. Moczar, "Glycosaminoglycans in elastase induced emphysema," Bulletin Européen de Physiopathologie Respiratoire, vol. 16, supplement, pp. 99-104, 1980.
95. J. O. Cantor, J. M. Cerreta, S. Keller, and G. M. Turino, "Modulation of airspace enlargement in elastase-induced emphysema by intratracheal instillment of hyaluronidase and hyaluronic acid," Experimental Lung Research, vol. 21, no. 3, pp. 423-436, 1995.
96. J. O. Cantor, J. M. Cerreta, G. Armand , and G. M. Turino, "Further investigation of the use of intratracheally administered hyaluronic acid to ameliorate elastase-induced emphysema," Experimental Lung Research, vol. 23, no. 3, pp. 229-244, 1997.
97. M. Scuri, W. M. Abraham, Y. Botvinnikova, and R. Forteza, "Hyaluronic acid blocks porcine pancreatic elastase (PPE)-induced bronchoconstriction in sheep," American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10, pp. 1855-1859, 2001.
98. M. Scuri and W. M. Abraham, "Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep," Pulmonary Pharmacology and Therapeutics, vol. 16, no. 6, pp. 335-340, 2003.
99. M. Scuri, J. R. Sabater, and W. M. Abraham, "Hyaluronan blocks porcine pancreatic elastase-inducedmucociliary dysfunction in allergic sheep," Journal of Applied Physiology, vol. 102, no. 6, pp. 2324-2331, 2007.
100. D. Negrini, A. Passi, G. De Luca, and G. Miserocchi, "Proteoglycan involvement during development of lesional pulmonary edema," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 274, no. 2, pp. L203-L211, 1998.
101. A. Passi, D. Negrini, R. Albertini, G. deLuca, and G. Miserocchi, "Involvement of lung interstitial proteoglycans in development of hydraulic-and elastase-induced edema," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 275, no. 3, pp. L631-L635, 1998.
102. R. D. Bland , "Edema formation in the lungs and its relationship to neonatal respiratory distress," Acta Paediatrica, vol. 72, supplement 305, pp. 92-99, 1983.
103. S. E. Juul, R. C. Krueger Jr., L. Scofield, M. B. Hershenson, and N. B. Schwartz, "Hyperoxia alone causes changes in lung proteoglycans and hyaluronan in neonatal rat pups," American Journal of Respiratory Cell and Molecular Biology, vol. 13, no. 6, pp. 629-638, 1995.
104. H. Johnsson, L. Eriksson, A. Jonzon, T. C. Laurent, and G. Sedin, "Lung hyaluronan and water content in pretermand termrabbit pups exposed to oxygen or air," Pediatric Research, vol. 44, no. 5, pp. 716-722, 1998.
105. R. L. Stedman, "The chemical composition of tobacco and tobacco smoke," Chemical Reviews, vol. 68, no. 2, pp. 153-207, 1968.
106. R. Vassallo and J. H. Ryu, "Smoking-related interstitial lung diseases," Clinics in Chest Medicine, vol. 33, no. 1, pp. 165-178, 2012.
107. J. O. Cantor, J. M. Cerreta, M. Ochoa, S. Ma, M. Liu, and G. M. Turino, "Therapeutic effects of hyaluronan on smoke-induced elastic fiber injury: does delayed treatment affect efficacy?" Lung, vol. 189, no. 1, pp. 51-56, 2011.
108. P.-M. Huang, O. Syrkina, L. Yu et al., "High MW hyaluronan inhibits smoke inhalation-induced lung injury and improves survival," Respirology, vol. 15, no. 7, pp. 1131-1139, 2010.
109. A. Bao, L. Liang, F. Li, M. Zhang, and X. Zhou, "Effects of acute ozone exposure on lung peak allergic inflammation of mice," Frontiers in Bioscience, vol. 18, no. 3, pp. 838-851, 2013.
110. F. Feng, Z. Li, E. N. Potts-Kant et al., "Hyaluronan activation of the Nlrp3 inflammasome contributes to the development of airway hyperresponsiveness," Environmental Health Perspectives, vol. 120, no. 12, pp. 1692-1698, 2012.
111. Z. Li, E. N. Potts-Kant, S. Garantziotis, W. M. Foster, and J. W. Hollingsworth, "Hyaluronan signaling during ozone-induced lung injury requires TLR4, MyD88, and TIRAP," PLoSONE, vol. 6, no. 11, Article ID e27137, 2011.
112. Z. Li, E. N. Potts, C. A. Piantadosi, W. M. Foster, and J. W. Hollingsworth, "Hyaluronan fragments contribute to the ozone-primed immune response to lipopolysaccharide," The Journal of Immunology, vol. 185, no. 11, pp. 6891-6898, 2010.
113. R. P. Hill, "Radiation effects on the respiratory system," BJR Supplement, vol. 27, pp. 75-81, 2005.
114. D. Rosenbaum, S. Peric, M. Holecek, and H. E. Ward, "Hyaluronan in radiation-induced lung disease in the rat," Radiation Research, vol. 147, no. 5, pp. 585-591, 1997.
115. Y. Li, M. Rahmanian, C. Widström, G. Lepperdinger, G. I. Frost, and P. Heldin, "Irradiation-induced expression of hyaluronan (HA) synthase 2 and hyaluronidase 2 genes in rat lung tissue accompanies active turnover ofHAand induction of types I and III collagen gene expression," American Journal of Respiratory Cell and Molecular Biology, vol. 23, no. 3, pp. 411-418, 2000.
116. M. Iwakawa, S. Noda, T. Ohta et al., "Strain dependent differences in a histological study of CD44 and collagen fibers with an expression analysis of inflammatory response-related genes in irradiated murine lung," Journal of Radiation Research, vol. 45, no. 3, pp. 423-433, 2004.
117. S. E. Juul, M. G. Kinsella, J. C. Jackson, W. E. Truog, T. A. Standaert, and W. A. Hodson, "Changes in hyaluronan deposition during early respiratory distress syndrome in premature monkeys," Pediatric Research, vol. 35, no. 2, pp. 238-243, 1994.
118. K. J. Bai, A. P. Spicer, M. M. Mascarenhas et al., "The role of hyaluronan synthase 3 in ventilator-induced lung injury," American Journal of Respiratory and Critical CareMedicine, vol. 172, no. 1, pp. 92-98, 2005.
119. X. Wang, Z. Sun, L. Qian et al., "Effects of hyaluronan-fortified surfactant in ventilated premature piglets with respiratory distress," Biology of the Neonate, vol. 89, no. 1, pp. 15-24, 2006.
120. S. Baron, Ed., Medical Microbiology, University of Texas Medical Branch at Galveston, Galveston, Tex, USA, 1996, http://www.ncbi.nlm.nih.gov/books/NBK7627/.
121. S. E. Juul, M. G. Kinsella, W. E. Truog, R. L. Gibson, and G. J. Redding, "Lung hyaluronan decreases during Group B Streptococcal pneumonia in neonatal piglets," American Journal of Respiratory and Critical Care Medicine, vol. 153, no. 5, pp. 1567-1570, 1996.
122. G. J. W. van der Windt, S. Florquin, A. F. de Vos et al., "CD44 deficiency is associated with increased bacterial clearance but enhanced lung inflammation during gram-negative pneumonia," The American Journal of Pathology, vol. 177, no. 5, pp. 2483-2494, 2010.
123. G. J. W. van der Windt, A. J. Hoogendijk, A. F. de vos, M. E. Kerver, S. Florquin, and T. Van Der Poll, "The role of CD44 in the acute and resolution phase of the host response during pneumococcal pneumonia," Laboratory Investigation, vol. 91, no. 4, pp. 588-597, 2011.
124. Z. Hasan, K. Palani, M. Rahman, and H. Thorlacius, "Targeting CD44 expressed on neutrophils inhibits lung damage in abdominal sepsis," Shock, vol. 35, no. 6, pp. 567-572, 2011.
125. C. Marion, J. M. Stewart, M. F. Tazi et al., "Streptococcus pneumoniae can utilize multiple sources of hyaluronic acid for growth," Infection and Immunity, vol. 80, no. 4, pp. 1390-1398, 2012.
126. O. N. Uchakina, C. M. Castillejo, C. C. Bridges, and R. J. McKallip, "The role of hyaluronic acid in SEB-induced acute lung inflammation," Clinical Immunology, vol. 146, no. 1, pp. 56-69, 2013.
127. R. J. McKallip, H. F. Hagele, and O. N. Uchakina, "Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses SEB-induced lung inflammation," Toxins, vol. 5, no. 10, pp. 1814-1826, 2013.
128. M. Y. Chang, Y. Tanino, V. Vidova et al., "Reprint of: a rapid increase in macrophage-derived versican and hyaluronan in infectious lung disease," Matrix Biology, vol. 35, pp. 162-173, 2014.
129. L. Zhuo, A. Kanamori, R. Kannagi et al., "SHAP potentiates the CD44-mediated leukocyte adhesion to the hyaluronan substratum," The Journal of Biological Chemistry, vol. 281, no. 29, pp. 20303-20314, 2006.
130. H. He, S. Zhang, S. Tighe, J. Son, and S. C. G. Tseng, "Immobilized heavy chain-hyaluronic acid polarizes lipopolysaccharideactivated macrophages toward m2 phenotype," The Journal of Biological Chemistry, vol. 288, no. 36, pp. 25792-25803, 2013.
131. M. E. Monzon, S. Casalino-Matsuda, and R. M. Forteza, "Identification of glycosaminoglycans in human airway secretions," The American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 2, pp. 135-141, 2006.
132. C. B. Basbaum and W. E. Finkbeiner, "Airway secretion: a cellspecific analysis," Hormone and Metabolic Research, vol. 20, no. 11, pp. 661-667, 1988.
133. J. N. Baraniuk, T. Shizari, M. Sabol, M. Ali, and C. B. Underhill, "Hyaluronan is exocytosed fromserous, but notmucous cells, of human nasal and tracheobronchial submucosal glands," Journal of Investigative Medicine, vol. 44, no. 2, pp. 47-52, 1996.
134. J. O. Cantor, J. M. Cerreta, G. Armand , and G. M. Turino, "Aerosolized hyaluronic acid decreases alveolar injury induced by human neutrophil elastase," Proceedings of the Society for Experimental Biology and Medicine, vol. 217, no. 4, pp. 471-475, 1998.
135. J. O. Cantor and G. M. Turino, "Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema?" Chest, vol. 125, no. 1, pp. 288-292, 2004.
136. P. P. Nadkarni, G. S. Kulkarni, J. M. Cerreta, S. Ma, and J. O. Cantor, "Dichotomous effect of aerosolized hyaluronan in a hamster model of endotoxin-induced lung injury," Experimental Lung Research, vol. 31, no. 9-10, pp. 807-818, 2005.
137. J. O. Cantor, J. M. Cerreta, M. Ochoa et al., "Aerosolizedhyaluronan limits airspace enlargement in a mouse model of cigarette smoke-induced pulmonary emphysema," Experimental Lung Research, vol. 31, no. 4, pp. 417-430, 2005.
138. G. Petrigni and L. Allegra, "Aerosolised hyaluronic acid prevents exercise-induced bronchoconstriction, suggesting novel hypotheses on the correction of matrix defects in asthma," Pulmonary Pharmacology & Therapeutics, vol. 19, no. 3, pp. 166-171, 2006.
139. C. Sondrup, Y. Liu, X. Z. Shu, G. D. Prestwich, and M. E. Smith, "Cross-linked hyaluronan-coated stents in the prevention of airway stenosis," Otolaryngology-Head and Neck Surgery, vol. 135, no. 1, pp. 28-35, 2006.
140. H. W. Taeusch, E. Dybbro, and K. W. Lu, "Pulmonary surfactant adsorption is increased by hyaluronan or polyethylene glycol," Colloids and Surfaces B: Biointerfaces, vol. 62, no. 2, pp. 243-249, 2008.
141. Y.-Y. Liu, C.-H. Lee, R. Dedaj et al., "High-molecular-weight hyaluronan-a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats," Critical Care, vol. 12, no. 4, article R102, 2008.
142. P. Buonpensiero, F. de Gregorio, A. Sepe et al., "Hyaluronic acid improves pleasantness and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis," Advances in Therapy, vol. 27, no. 11, pp. 870-878, 2010.
143. J.-M. Zahm, M. Milliot, A. Bresin, C. Coraux, and P. Birembaut, "The effect of hyaluronan on airway mucus transport and airway epithelial barrier integrity: potential application to the cytoprotection of airway tissue," Matrix Biology, vol. 30, no. 7-8, pp. 389-395, 2011.
144. L. M. Carro, A. L. Ferreiro, M. R. de Valbuena Máiz, C. W. Struwing, G. G. Álvarez, and L. S. Cortina, "Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis," Medicina Clinica, vol. 138, no. 2, pp. 57-59, 2012.
145. M. L. Furnari, L. Termini, G. Traverso et al., "Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, rand omized, double-blind, controlled study," Therapeutic Advances in Respiratory Disease, vol. 6, no. 6, pp. 315-322, 2012.
146. A. Macchi, P. Terranova, E. Digilio, and P. Castelnuovo, "Hyaluronan plus saline nasal washes in the treatment of rhino-sinusal symptoms in patients undergoing functional endoscopic sinus surgery for rhino-sinusal remodeling," International Journal of Immunopathology and Pharmacology, vol. 26, no. 1, pp. 137-145, 2013.
147. F. Cresta, A. Naselli, F. Favilli, and R. Casciaro, "Inhaled hypertonic saline+hyaluronic acid in cystic fibrosis with asthma-like symptoms: a new therapeutic chance," BMJ Case Reports, vol. 2013, 2013.
148. K. W. Lu, H. W. Taeusch, and J. A. Clements, "Hyaluronan with dextran added to therapeutic lung surfactants improves effectiveness in vitro and in vivo," Experimental Lung Research, vol. 39, no. 4-5, pp. 191-200, 2013.
149. A. Macchi, P. Castelnuovo, P. Terranova, and E. Digilio, "Effects of sodiumhyaluronate in childrenwith recurrent upper respiratory tract infections: results of a rand omised controlled study," International Journal of Immunopathology and Pharmacology, vol. 26, no. 1, pp. 127-135, 2013.
150. M. Ros, R. Casciaro, F. Lucca et al., "Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, rand omized, controlled clinical trial," Journal of Aerosol Medicine and Pulmonary Drug Delivery, vol. 27, no. 2, pp. 133-137, 2014.